



## NEWS RELEASE

### IZOTROPIC CORPORATION ANNOUNCES ADOPTION OF LONG-TERM INCENTIVE PLAN

**VANCOUVER, BC – July 10, 2020 – Izotropic Corporation (“Izotropic” or the “Company”)** (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce that its board of directors has adopted a long-term incentive plan (the “LTIP”), for the purpose of attracting, retaining and motivating key individuals.

A total of 2,996,549 common shares, being 10% of the total number of issued and outstanding common shares on the date of adoption of the LTIP, are issuable under the LTIP.

ON BEHALF OF THE BOARD

Robert Thast  
Chief Executive Officer

#### About Izotropic Corp.

Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.

Approximately \$20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research

1-833-IZOCORP

izocorp.com  
info@izocorp.com

Suite 424, 800-15355 24th Avenue  
Surrey BC Canada, V4A 2H9

includes a current, ongoing \$2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Phone: 1-833-IZOCORP

Email: [info@izocorp.com](mailto:info@izocorp.com)

Website: [izocorp.com](http://izocorp.com)